Pfizer is suing Metsera and Novo Nordisk over an emerging obesity drug developer. Pfizer accuses Novo and Metsera of breaching the terms of their buyout deal, claiming fiduciary duties violations. Pfizer seeks to block Metsera from terminating their contract while the case is ongoing. Novo’s bid is seen as a threat to Pfizer’s acquisition.

Novo made a $6.5 billion upfront bid for Metsera, triggering Pfizer’s response. Pfizer calls Novo’s proposal reckless and unprecedented, hinting at legal action. Pfizer claims Novo’s deal faces regulatory delays, while Pfizer has early FTC clearance. Pfizer’s lawsuit alleges violations of Delaware law and fiduciary duties by Metsera’s board.

Metsera disputes Pfizer’s claims and plans to address them in court. Analysts see Pfizer’s actions as pressure tactics to halt Novo’s bid and seek government intervention. Pfizer’s move is seen as an attempt to protect its acquisition of Metsera and prevent competition suppression. Novo has not yet commented on the situation.

Read more at Yahoo Finance: Pfizer sues Metsera, Novo in effort to enforce buyout deal